Skip to main content

Table 3 Risk for myocardial infarction, coronary heart disease, stroke and peripheral artery disease following myocardial infarction

From: Risk for recurrent cardiovascular disease events among patients with diabetes and chronic kidney disease

  Prior CVD
(n = 89,920)
Diabetes only
(n = 46,032)
CKD only
(n = 13,459)
Diabetes and CKD
(n = 13,319)
Myocardial infarction
 Number of events 14,350 5725 1894 2562
 Incidence Rate (95% CI) 84 (82, 85) 63 (62, 64) 85 (81, 89) 117 (113, 122)
Hazard ratio (95% CI)
 Model 1 1.00 (ref) 0.83 (0.80–0.85) 0.89 (0.85–0.94) 1.30 (1.24–1.35)
 Model 2 1.00 (ref) 0.88 (0.85–0.91) 0.92 (0.87–0.96) 1.25 (1.20–1.31)
Coronary heart disease
 Number of events 18,741 8055 2266 3051
 Incidence Rate (95% CI) 114 (113, 116) 92 (90, 94) 105 (100, 109) 145 (140, 150)
Hazard ratio (95% CI)
 Model 1 1.00 (ref) 0.85 (0.82–0.87) 0.86 (0.82–0.90) 1.20 (1.16–1.25)
 Model 2 1.00 (ref) 0.91 (0.88–0.94) 0.90 (0.86–0.94) 1.19 (1.14–1.24)
Stroke
 Number of events 3019 1342 401 469
 Incidence Rate (95% CI) 16 (16, 17) 14 (13, 15) 17 (15, 18) 19 (18, 21)
Hazard ratio (95% CI)
 Model 1 1.00 (ref) 0.98 (0.91–1.04) 0.87 (0.79–0.97) 1.11 (1.01–1.23)
 Model 2 1.00 (ref) 1.00 (0.93–1.08) 0.87 (0.78–0.97) 1.09 (0.98–1.20)
Peripheral artery disease
 Number of events 1238 577 104 241
 Incidence Rate (95% CI) 7 (6, 7) 6 (5, 6) 4 (3, 5) 10 (9, 11)
Hazard ratio (95% CI)
 Model 1 1.00 (ref) 0.85 (0.77–0.94) 0.65 (0.53–0.79) 1.32 (1.15–1.52)
 Model 2 1.00 (ref) 0.92 (0.83–1.03) 0.66 (0.54–0.81) 1.28 (1.11–1.49)
  1. CI confidence interval, CKD chronic kidney disease, CVD cardiovascular disease Incidence rates are presented as per 1000 person-years
  2. Model 1 includes adjustment for age, sex, race/ethnicity (for patients in the Medicare sample), geographic region of residence and area-level income (for patients in the Medicare sample)
  3. Model 2 includes adjustment for Model 1 plus smoking, hypertension, depression, history of heart failure, cardiologist care, endocrinologist care, antihypertensive medication use, statin therapy and intensity, and ezetimibe use